S. Manunta

Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?

A. Goldhirsch, G. Curigliano, L. Mazzarella, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report.

A. Rocca, A. Curcio, R. Maltoni, 2020, World journal of clinical cases.

Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

L. Crinò, A. Delmonte, G. Bronte, 2022, Cancers.

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience

U. de Giorgi, A. Vagheggini, A. Fedeli, 2020, Diagnostics.

Tumour dormancy and clinical implications in breast cancer

A. Goldhirsch, C. Criscitiello, G. Curigliano, 2013, Ecancermedicalscience.

Infections in lung cancer patients undergoing immunotherapy and targeted therapy: an overview on the current scenario.

S. Novello, C. Solinas, M. Scartozzi, 2023, Critical reviews in oncology/hematology.

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

R. Gelber, A. Goldhirsch, F. Cardoso, 2015, Breast.

Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials.

A. Goldhirsch, C. Criscitiello, G. Curigliano, 2013, Cancer treatment reviews.

Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer

A. Rocca, S. Bravaccini, R. Maltoni, 2020, Cell transplantation.

How to discriminate non-small cell lung cancer (NSCLC) cases from an Italian administrative database? A retrospective, secondary data use study for evaluating a novel algorithm performance

L. Crinò, A. Delmonte, I. Massa, 2021, BMJ Open.